Why B cells?
Therapeutic interventions for immunological diseases have largely focused on T cells for the last 30 years. However, the importance of B cells during disease development and clinical management has become evident with therapies that globally deplete or target all B cells, such as the monoclonal antibody RITUXAN® (rituximab).
Specific B cell subsets are now known to serve critical regulatory functions during immune responses, and B cells provide essential protective functions during infections. Therapies that selectively target specific B cell subsets and their functions remain elusive.
Our proprietary technology platforms focus on unique aspects of regulatory B lymphocyte (B10 cell) biology that are involved in controlling a variety of autoimmune diseases, inflammatory immune responses and cancer immunotherapy. B10 cells represent a small subset of B cells that reduces immune responses and autoimmunity through their capacity to secrete interleukin 10 (IL-10), a potent inhibitory cytokine.
We are advancing two B10 cell-based technologies that can either enhance or inhibit immune responses. We believe this technology has the potential to profoundly advance treatments for inflammation, autoimmunity, solid tumors and infection.
Our first-in-class regulatory B10 cell-directed therapies are unique in their approach and distinguish us from others working in the immunotherapy area. We have one of the leading pipelines in B cell therapy.
The science behind our technology is well-vetted and supported by numerous peer-reviewed publications.